Abstract
Phytochemicals are rich source of bioactive constituents and can be used as another alternative to currently used drugs for diseases like Diabetes mellitus. The potential of Isoliquiritigenin (a constituent of Pterocarpus marsupium) as PPAR𝛾 agonist was evaluated by in silico technique. Autodock results showed that Tyr327, and Tyr473 of the PPARγ forms H-bonds with Isoliquiritigenin (binding energy of -7.46 kcal/mol) and Troglitazone (known drug) showed H bond with Tyr327, Ser289, with binding energy of -11.01 kcal/mol. Isoliquiritigenin, binding energy in Extra precision (XP) was -6.74 kcal/mol while Troglitazone docking, gave binding energy in XP mode as -9.59 kcal/mol. The best Induced fit docking (IFD) score of the optimised PPARγ- Isoliquiritigenin complexes was -9.39 Kcal/mol. The important residues in IFD forming H bond were Cys 285, Arg 288, Tyr 327 and Leu 340. The post docking MM/GBSA free energy for PPARγ with Isoliquiritigenin and Troglitazone was -49.29 and -71.48 Kcal/mol respectively. Binding interaction in MD simulation and Principal Component Analysis studies revealed stable binding throughout 100 ns simulation. Post Simulation MM/PBSA free energy was calculated. The results indicated that compound possessed a negative binding free energy with -114.37KJ/mol. It was observed that van der Waals, electrostatic interactions and non-polar solvation energy negatively contributed to the total interaction energy while only polar solvation energy positively contributed to total free binding energy. The Isoliquiritigenin fulfils the criteria of drug-likeness property. Thus, study presents a systematic analysis on molecular mechanism of action of Isoliquiritigenin as PPARγ agonist in controlling Diabetes mellitus.
Effect of a Tertiary Butyl Group on Polar Solvation Dynamics in Aqueous Solution: A Computational Approach
